Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial
- PMID: 35704788
- DOI: 10.1200/JCO.22.00669
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial
Comment in
-
Reply to S. Zeng et al.J Clin Oncol. 2022 Sep 10;40(26):3094-3095. doi: 10.1200/JCO.22.01031. Epub 2022 Jun 15. J Clin Oncol. 2022. PMID: 35704836 No abstract available.
Comment on
-
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
